SepctraMax i3x Multi Mode Microplate Detection Platform (Toxicology)

The Food and Drug Administration is forecasting the purchase of a SpectraMax i3x Multi-Mode Microplate Detection Platform to support research in hepatotoxicity under the HFP priority area. This equipment acquisition is intended to enhance the agency’s capacity for high-throughput toxicological analysis, enabling more precise and efficient evaluation of compound-induced liver injury. The procurement is categorized under NAICS code 541990, indicating it falls within other scientific and technical consulting services, aligning with the research-focused nature of the project. The opportunity was posted on May 25, 2026, and is currently in the forecasting phase with no solicitation number assigned or set-aside designation specified. The point of contact for program-related inquiries is the Hfp Acquisition Liaison at hfpacquisitions@fda.hhs.gov, while the contracting officer position remains to be determined. The place of performance and organizational address details have not been provided, indicating the equipment will likely be deployed at an FDA facility involved in toxicology research. This forecast signals the agency’s intent to modernize its analytical infrastructure to meet evolving scientific demands in food and drug safety assessment.